PGNY Progyny, Inc.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1551306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.5%
TTM net income YoY60.9%
TTM EPS YoY73.0%
Revenue 3-yr CAGR9.0%
Net income 3-yr CAGR20.5%
Margins
Gross margin24.9%
Operating margin9.4%
Net margin6.8%
FCF margin13.4%
EBITDA margin9.9%
Returns
ROE18.7%
ROA12.4%
ROIC (approx.)23.9%
Asset turnover1.82x
Leverage & solvency
Liabilities / assets38.7%
Debt / equity0.00x
Current ratio1.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.28x
Accruals ratio-15.8%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.29B | $1.17B |
| Cost of revenue | $984.18M | $913.86M |
| Gross profit | $304.48M | $253.36M |
| R&D expense | $9.50M | — |
| SG&A expense | $147.09M | $121.96M |
| Operating income | $85.28M | $67.45M |
| Pretax income | $95.43M | $83.20M |
| Income tax | $36.91M | $28.87M |
| Net income | $58.52M | $54.34M |
| EBITDA | $90.22M | $70.63M |
| EPS (basic) | 0.68 | 0.59 |
| EPS (diluted) | 0.65 | 0.57 |
| Weighted avg. shares (diluted) | 89.86M | 95.45M |
| Balance sheet | ||
| Cash & equivalents | $112.24M | $162.31M |
| Short-term investments | $197.86M | $65.64M |
| Receivables | $220.29M | $235.32M |
| Current assets | $551.77M | $472.72M |
| PP&E, net | $29.93M | $12.38M |
| Goodwill | $19.98M | $15.53M |
| Intangibles | $6.22M | $1.30M |
| Total assets | $742.43M | $607.10M |
| Current liabilities | $202.39M | $168.63M |
| Total liabilities | $226.39M | $185.04M |
| Shareholders' equity | $516.04M | $422.06M |
| Shares outstanding | 83.37M | 85.31M |
| Cash flow statement | ||
| Operating cash flow | $210.19M | $179.10M |
| Capital expenditure | $18.41M | $5.41M |
| Free cash flow | $191.78M | $173.70M |
| Investing cash flow | -$159.01M | $195.79M |
| Financing cash flow | -$99.36M | -$309.88M |
| Depreciation & amortization | $4.95M | $3.17M |
| Stock-based compensation | $131.87M | $128.13M |
| Share buybacks | $81.66M | $300.28M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.